Melanoma & Skin Cancer | Specialty

Dr. Ascierto on Triplet Therapy in BRAF+ Melanoma

August 31st 2018

Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses investigational triplet therapies in patients with BRAF-positive melanoma.

Adjuvant Dabrafenib/Trametinib Approved in Europe for BRAF+ Melanoma

August 29th 2018

The European Commission has approved the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the adjuvant treatment of patients with BRAF V600–positive stage III melanoma.

Dr. Tarhini on Recent Practice-Changing Clinical Trials in Melanoma

August 21st 2018

Ahmad Tarhini, MD, PhD, director, Melanoma and Skin Cancer Program, Center for Immuno-Oncology Research, Cleveland Clinic, discusses some recent practice-changing clinical trials in melanoma.

Neoadjuvant Immunotherapy Emerges as a New Frontier

August 20th 2018

Although checkpoint blocking immunotherapy has significantly improved outcomes for patients with advanced and metastatic disease, researchers believe the modality also may be effective in the neoadjuvant setting.

Dr. Stilwill on Findings from the 2018 ASCO Annual Meeting in Melanoma

August 1st 2018

Joseph Stilwill, MD, medical oncologist, Sarah Cannon Research Institute, discusses exciting findings in melanoma from the 2018 ASCO Annual Meeting.

Adjuvant Nivolumab Approved in Europe for Melanoma

July 31st 2018

The European Commission has approved nivolumab (Opdivo) as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease, regardless of BRAF mutation status.

Dr. Nghiem on Response to Immunotherapy in Merkel Cell Carcinoma

July 31st 2018

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses response to immunotherapy in Merkel cell carcinoma.

Adjuvant Dabrafenib/Trametinib Nears European Approval for BRAF+ Melanoma

July 27th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of the combination of dabrafenib and trametinib for the adjuvant treatment of adult patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.

Binimetinib/Encorafenib Combo Approaches European Approval for BRAF+ Melanoma

July 27th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for the treatment of adult patients with BRAF V600–mutant unresectable or metastatic melanoma.

Pembrolizumab Approved in China for Melanoma

July 27th 2018

The China National Drug Administration has approved pembrolizumab (Keytruda) for the treatment of adult patients with unresectable or metastatic melanoma after 1 prior line of therapy.

Adjuvant Therapy in Melanoma: What's Coming Next?

July 26th 2018

Considerations Surrounding Adjuvant Therapy in Melanoma

July 26th 2018

Using Adjuvant Therapy in Patients With Melanoma

July 26th 2018

Adjuvant Therapy for Melanoma: Novel Treatment Options

July 26th 2018

Molecular Testing in Stage 3 Melanoma

July 26th 2018

Future Outlook: Treating Advanced Melanoma

July 26th 2018

Emerging Combination Regimens in Advanced Melanoma

July 26th 2018

The COLUMBUS Trial in Melanoma

July 26th 2018

Potential Role of Neoadjuvant Therapy in Melanoma

July 26th 2018

Managing Disease Progression in Metastatic Melanoma

July 26th 2018